18420725. MCT4-TARGETED THERAPEUTICS PREVENTING AKI TO CKD TRANSITION simplified abstract (Northwestern University)
MCT4-TARGETED THERAPEUTICS PREVENTING AKI TO CKD TRANSITION
Organization Name
Inventor(s)
Pinelopi Kapitsinou of Evanston IL (US)
Ratnakar Tiwari of Evanston IL (US)
MCT4-TARGETED THERAPEUTICS PREVENTING AKI TO CKD TRANSITION - A simplified explanation of the abstract
This abstract first appeared for US patent application 18420725 titled 'MCT4-TARGETED THERAPEUTICS PREVENTING AKI TO CKD TRANSITION
- Simplified Explanation:**
This patent application discloses agents, compositions, and methods for treating acute kidney injury (AKI) by inhibiting or reducing the expression of monocarboxylate transporter 4 (MCT4) to prevent the progression from AKI to chronic kidney disease.
- Key Features and Innovation:**
- Treatment of acute kidney injury (AKI)
- Reduction of progression from AKI to chronic kidney disease
- Inhibition of monocarboxylate transporter 4 (MCT4) expression
- Potential Applications:**
This technology could be applied in the medical field for the treatment of AKI and prevention of chronic kidney disease.
- Problems Solved:**
This technology addresses the need for effective treatments for AKI and strategies to reduce the risk of developing chronic kidney disease.
- Benefits:**
- Improved outcomes for patients with AKI
- Reduced incidence of chronic kidney disease
- Enhanced understanding of the role of MCT4 in kidney injury
- Commercial Applications:**
The technology could have commercial applications in pharmaceuticals for the development of new treatments for AKI and chronic kidney disease, potentially impacting the healthcare market.
- Questions about Acute Kidney Injury:**
1. What are the common causes of acute kidney injury? 2. How does inhibiting MCT4 expression help in treating AKI?
- Frequently Updated Research:**
Researchers are continually studying the role of MCT4 in kidney injury and exploring new therapeutic approaches for AKI treatment.
Original Abstract Submitted
Disclosed are agents, compositions, and methods for treating acute kidney injury (AKI). Particularly disclosed are agents, compositions, and methods for treating AKI and reducing the progression from AKI to chronic kidney disease by administering an agent that inhibits or reduces expression of monocarboxylate transporter 4 (MCT4).
